No Data
No Data
Beijing Chieftain Control Engineering Technology (300430.SZ): released three non-invasive brain-computer interface prototype products mainly focused on neurorehabilitation.
On July 12, Gelunhui reported that Beijing Chieftain Control Engineering Technology (stock code 300430.SZ) expressed on the investor interaction platform that they were sorry for not releasing news immediately after the press conference ended. They will continue to improve their level and ability in investor relations management. The product prototype conference of the company's brain-computer interface was held as scheduled on July 10th, and the main focus was on releasing three non-invasive brain-computer interface prototype products in the field of neural rehabilitation.
Beijing Chieftain Control Engineering Technology (300430.SZ): The rehabilitation medical devices sector is exploring and applying brain-computer interface technology.
On July 12, Gelonhui reported that Beijing Chieftain Control Engineering Technology (300430.SZ) said on the investor interaction platform that the company's rehabilitation medical device sector is exploring and applying brain-computer interface technology, mainly cooperating with the Tsinghua University team. Brain-computer interfaces are mainly divided into non-invasive and invasive types. In the non-invasive aspect, the company will first integrate with Longzhi Jie's existing rehabilitation products to achieve functional upgrades of the existing rehabilitation products. On July 10, the company released three non-invasive product prototypes. In terms of invasive aspects, in May 2024, the company's subsidiary Beijing Brain-Link Technology Co., Ltd. and the management committee of the Daxing Pharmaceutical Base jointly
Beijing Chieftain Control Engineering Technology (300430.SZ) plans to pay 0.55 yuan per 10 shares in 2023, with ex-dividend and ex-rights on July 9.
Chieftain Control Engineering Technology (300430.SZ) announced on the Smart Finance and Economics App that the company plans to distribute cash dividends of RMB 0.55 per 10 shares to all shareholders in 2023, with the record date on July 8, 2024 and the ex-dividend date on July 9, 2024.
Chengyitong (300430.SZ): The core product automated biological fermentation control system has many applications in the field of synthetic biology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Are there synthetic biological-related technologies currently being developed by the company?” The company replied that downstream customers in the company's intelligent manufacturing sector mainly include pharmaceutical and biological manufacturing companies. Biomaneling is mainly a production method using synthetic biotechnology as an important technical support and biological fermentation process as an important means of implementation. The company's core product, the automated biological fermentation control system, has many applications in the field of synthetic biology. Driven by synthetic biotechnology and green biological manufacturing, 202
Chengyitong (300430.SZ): Currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of invasive technology
Gelonghui, May 9, 丨 Chengyitong (300430.SZ) held a performance briefing on May 8, 2024 to discuss “Can the brain-computer products the company is developing regenerate insulin to treat diabetes?” The company replied that currently, the company is focusing on the market-based implementation of non-intrusive brain-computer interface technology and the R&D and development of intrusive technology. In planning non-invasive technology, the company integrates existing rehabilitation products with brain-computer interfaces to achieve product upgrades, thereby providing more effective rehabilitation services for patients with neurological diseases. In the future, the company will also focus on the application of brain-computer interfaces in other medical fields
Chengyitong (300430.SZ) announced first-quarter results, net profit of 307.813 million yuan, an increase of 37.71%
Chengyitong (300430.SZ) released its report for the first quarter of 2024, achieving 2.68 operating income during the reporting period...
No Data